CLINICAL TRIALS PROFILE FOR OLTIPRAZ
✉ Email this page to a colleague
Clinical Trials for Oltipraz
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00006457 ↗ | Oltipraz in the Prevention of Lung Cancer in People Who Smoke | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung cancer in people who smoke. |
NCT00006457 ↗ | Oltipraz in the Prevention of Lung Cancer in People Who Smoke | Completed | Northwestern University | Phase 1 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung cancer in people who smoke. |
NCT00956098 ↗ | Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis | Completed | CJ HealthCare Corporation | Phase 2 | This study investigated the effectiveness and safety of oltipraz therapy in treating patients with cirrhosis induced by chronic hepatitis type B or C. |
NCT00956098 ↗ | Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis | Completed | HK inno.N Corporation | Phase 2 | This study investigated the effectiveness and safety of oltipraz therapy in treating patients with cirrhosis induced by chronic hepatitis type B or C. |
NCT01373554 ↗ | Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease | Completed | PharmaKing | Phase 2 | Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK) activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1 (S6K1) inhibition. And it is well known that the modulation of S6K1 by oltipraz inhibited the development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway.Also some research reported that LXRg (a member of the nuclear hormone receptor)-mediated increases in SREBP-1c (the sterol regulatory element-binding protein-1c gene) promote the expression of lipogenic genes and enhance fatty acid synthesis and oltipraz inhibits LXRg and SREBP-c. Therefore, Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Oltipraz
Condition Name
Clinical Trial Locations for Oltipraz
Trials by Country
Clinical Trial Progress for Oltipraz
Clinical Trial Phase
Clinical Trial Sponsors for Oltipraz
Sponsor Name